Skip to main content

Advertisement

SpringerLink
Log in

mRNA biotherapeutics landscape for rare genetic disorders

  • Review
  • Published:
Journal of Biosciences Aims and scope Submit manuscript

Abstract

The medical emergency of COVID-19 brought to the forefront mRNA vaccine technology where the mRNA vaccine candidates mRNA-1273 and BNT162b2 displayed superlative and more than 90% efficacy in protecting against SARS-CoV2 infections. Rare genetic disorders are rare individually, but collectively they are common and represent a medical emergency. In mRNA biotherapeutic technology, administration of a therapeutic protein-encoding mRNA-nanoparticle formulation allows for in vivo production of therapeutic proteins to functionally complement the protein functions lacking in rare disease patients. The platform nature of mRNA biotherapeutic technology propels rare disease drug discovery and, owing to the scalable and synthetic nature of mRNA manufacturing, empowers parallel product development using a universal production pipeline. This review focuses on the advantages of mRNA biotherapeutic technology over current therapies for rare diseases and provides summaries for the proof-of-concept preclinical studies performed to demonstrate the potential of mRNA biotherapeutic technology. Apart from preclinical studies, this review also spotlights the clinical trials currently being conducted for mRNA biotherapeutic candidates. Currently, seven mRNA biotherapeutic candidates have entered clinical trials for rare diseases, and of them, 3 candidates entered in the year 2023 alone. The rapid pace of clinical development promises a future where, as with mRNA vaccines for COVID-19, mRNA biotherapeutic technology would combat an emergency of rare genetic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Akinc A, Maier MA, Manoharan M, et al. 2019 The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14 1084–1087

    Article  ADS  CAS  PubMed  Google Scholar 

  • Al Hafid N and Christodoulou J 2015 Phenylketonuria: a review of current and future treatments. Transl. Pediatr. 4 304–317

    PubMed  PubMed Central  Google Scholar 

  • Alton EWFW AD, Ashby D, et al. on behalf of the UK Cystic Fibrosis Gene Therapy Consortium 2016 A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis (https://www.ncbi.nlm.nih.gov/books/NBK373648/)

  • An D, Schneller JL, Frassetto A, et al. 2017 Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21 3548–3558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • An D, Frassetto A, Jacquinet E, Eybye M, et al. 2019 Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. eBioMedicine 45 519–528

  • Anderson BR, Muramatsu H, Nallagatla SR, et al. 2010 Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38 5884–5892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anderson EJ, Creech CB, Berthaud V, et al. 2022 Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. N. Engl. J. Med. 387 1673–1687

    Article  CAS  PubMed  Google Scholar 

  • Antoniou P, Miccio A and Brusson M 2021 Base and prime editing technologies for blood disorders. Front. Genome Ed. 3

  • Asrani KH, Farelli JD, Stahley MR, et al. 2018 Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 15 756–762

    PubMed  PubMed Central  Google Scholar 

  • August A, Attarwala HZ, Himansu S, et al. 2021 A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27 2224–2233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baden LR, El Sahly HM, Essink B, et al. 2021 Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384 403–416

    Article  CAS  PubMed  Google Scholar 

  • Bailey AL and Cullis PR 1994 Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry 33 12573–12580

    Article  CAS  PubMed  Google Scholar 

  • Baker RE and Shiman R 1979 Measurement of phenylalanine hydroxylase turnover in cultured hepatoma cells. J. Biol. Chem. 254 9633–9639

    Article  CAS  PubMed  Google Scholar 

  • Baruteau J, Cunningham SC, Yilmaz BS, et al. 2021 Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Mol. Ther. Methods. Clin. Dev. 23 135–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bavli Y, Chen B-M, Gross G, et al. 2023 Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). J. Control. Release 354 316–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Benenato K, Kumarasinghe ES and Cornebise M 2017 Compounds and compositions for intracellular delivery of therapeutic agents. US patent US20170210697

  • Bhandari JTP and Yadav D 2022 Crigler-Najjar syndrome (StatPearls Publishing) (https://www.ncbi.nlm.nih.gov/books/NBK562171/)

  • Bhat B, Karve S and Anderson DG 2021 mRNA therapeutics: beyond vaccine applications. Trends Mol. Med. 27 923–924

    Article  CAS  PubMed  Google Scholar 

  • Bin Sawad A, Jackimiec J, Bechter M, et al. 2022 Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review. Mol. Genet. Metab. 137 153–163

    Article  CAS  PubMed  Google Scholar 

  • Blankenship CS 2008 To manage costs of hemophilia, patients need more than clotting factor. Biotechnol. Healthc. 5 37–40

    PubMed  PubMed Central  Google Scholar 

  • Blankenship K 2019 Alnylam wins FDA nod for $575,000 liver med Givlaari despite safety flags (https://www.fiercepharma.com/pharma/alnylam-scores-fda-approval-for-rare-liver-disease-med-givlaari)

  • Büning H 2013 Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol. Med. 5 1–3

    Article  PubMed  PubMed Central  Google Scholar 

  • Burke T, Asghar S, O’Hara J, et al. 2021 Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys. Orphanet J. Rare Dis. 16 143

    Article  PubMed  PubMed Central  Google Scholar 

  • Cacicedo ML, Weinl-Tenbruck C, Frank D, et al. 2022a Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Front. Bioeng. Biotechnol. 10 993298

    Article  PubMed  PubMed Central  Google Scholar 

  • Cacicedo ML, Weinl-Tenbruck C, Frank D, et al. 2022b mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model. Mol. Ther. Methods. Clin. Dev. 26 294–308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cao J, An D, Galduroz M, et al. 2019 mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency. Mol. Ther. 27 1242–1251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cao J, Novoa EM, Zhang Z, et al. 2021a High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies. Nat. Commun. 12 4138

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Cao J, Choi M, Guadagnin E, et al. 2021b mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat. Commun. 12 3090

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Chander N, Basha G, Yan Cheng MH, et al. 2023 Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues. Mol. Ther. Methods Clin. Dev. 30 235–245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chavin SI 1984 Factor VIII: structure and function in blood clotting. Am. J. Hematol. 16 297–306

    Article  CAS  PubMed  Google Scholar 

  • Chen C-Y, Tran DM, Cavedon A, et al. 2020 Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles. Mol. Ther. Nucleic Acids 20 534–544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen R, Wang SK, Belk JA, et al. 2023a Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41 262–272

    Article  CAS  PubMed  Google Scholar 

  • Chen T, Gao Y, Zhang S, et al. 2023b Methylmalonic acidemia: Neurodevelopment and neuroimaging. Front. Neurosci. 17 1110942

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheng Q, Wei T, Jia Y, et al. 2018 Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv. Mater. 30 e1805308

    Article  PubMed  Google Scholar 

  • Cheng Q, Wei T, Farbiak L, et al. 2020 Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15 313–320

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Chou JY and Mansfield BC 2008 Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum. Mutat. 29 921–930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Connolly B, Isaacs C, Cheng L, et al. 2018 SERPINA1 mRNA as a treatment for Alpha-1 antitrypsin deficiency. J. Nucleic Acids 2018 8247935

    Article  PubMed  PubMed Central  Google Scholar 

  • Corbett KS, Edwards DK, Leist SR, et al. 2020 SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586 567–571

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Cui T, Li B and Li W 2022 NTLA-2001: opening a new era for gene therapy. Life Med. 1 49–51

    Article  Google Scholar 

  • Da Silva Sanchez A, Paunovska K, Cristian A, et al. 2020 Treating cystic fibrosis with mRNA and CRISPR. Hum. Gene. Ther. 31 940–955

    Article  PubMed  PubMed Central  Google Scholar 

  • Dass CR 2004 Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J. Mol. Med. 82 579–591

    Article  CAS  PubMed  Google Scholar 

  • Davies JC, Alton EW and Bush A 2007 Cystic fibrosis. Br. Med. J. 335 1255–1259

    Article  Google Scholar 

  • de Castro MJ, de Lamas C, Sánchez-Pintos P, et al. 2020 Bone status in patients with phenylketonuria: a systematic review. Nutrients 12

  • De Sabbata G, Boisgerault F, Guarnaccia C, et al. 2021 Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. Mol. Ther. Methods. Clin. Dev. 20 169–180

    Article  PubMed  Google Scholar 

  • DeRosa F, Smith L, Shen Y, et al. 2019 Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy. Mol. Ther. 27 878–889

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dilliard SA and Siegwart DJ 2023 Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8 282–300

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Eng CM, Guffon N, Wilcox WR, et al. 2001 Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N. Engl. J. Med. 345 9–16

    Article  CAS  PubMed  Google Scholar 

  • Fagerhol MK and Laurell CB 1970 The Pi system-inherited variants of serum alpha 1-antitrypsin. Prog. Med. Genet. 7 96–111

    CAS  PubMed  Google Scholar 

  • Felgner PL, Gadek TR, Holm M, et al. 1987 Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84 7413–7417

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Ferreira CR 2019 The burden of rare diseases. Am. J. Med. Genet. A 179 885–892

    Article  PubMed  Google Scholar 

  • Filion MC and Phillips NC 1997 Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329 345–356

    Article  CAS  PubMed  Google Scholar 

  • Flotte TR, Zeitlin PL, Daifuku R, et al. 1997 A Phase I study of AAV-CFTR administration in adult cystic fibrosis patients 1794. Pediatr. Res. 41 301–301

    Article  Google Scholar 

  • Fraser JL and Venditti CP 2016 Methylmalonic and propionic acidemias: clinical management update. Curr. Opin. Pediatr. 28 682–693

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Germain DP 2010 Fabry disease. Orphanet J. Rare Dis. 5 30

    Article  PubMed  PubMed Central  Google Scholar 

  • Gillmore JD, Gane E, Taubel J, et al. 2021 CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New. Engl. J. Med. 385 493–502

    Article  CAS  PubMed  Google Scholar 

  • Global Data Healthcare 2023 Moderna confirms progress in mRNA-3927 clinical trial (https://www.clinicaltrialsarena.com/comment/moderna-mrna-3927-clinical-trial/)

  • Gordon N 2003 Ornithine transcarbamylase deficiency: a urea cycle defect. Eur. J. Paediatr. Neurol. 7 115–121

    Article  PubMed  Google Scholar 

  • Greene CM, Marciniak SJ, Teckman J, et al. 2016 α1-Antitrypsin deficiency. Nat. Rev. Dis. Primers 2 16051

    Article  PubMed  Google Scholar 

  • Greig JA, Nordin JML, Draper C, et al. 2018 AAV8 gene therapy rescues the newborn phenotype of a mouse model of Crigler-Najjar. Hum. Gene Ther. 29 763–770

    Article  CAS  PubMed  Google Scholar 

  • Greig JA, Chorazeczewski JK, Chowdhary V, et al. 2023 Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model. Mol. Ther. Methods Clin. Dev. 29 32–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gribben JG, Devereux S, Thomas NSB, et al. 1990 Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335 434–437

    Article  CAS  PubMed  Google Scholar 

  • Grünert SC, Müllerleile S, De Silva L, et al. 2013 Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J. Rare Dis. 8 6

    Article  PubMed  PubMed Central  Google Scholar 

  • Grunewald SS, S; Koeberl,D; Schulze,A;, et al. 2023 ModernaTX, Inc. mRNA-3927 therapy for propionic acidemia: interim data from a Phase 1/2 study (https://s29.q4cdn.com/435878511/files/doc_presentations/2023/May/18/mrna-3927-pa-p101-ia-oral_asgct2023_final.pdf)

  • Guggino WB and Cebotaru L 2017 Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin. Biol. Ther. 17 1265–1273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gurung S, Timmermand OV, Perocheau D, et al. 2022 mRNA therapy restores ureagenesis and corrects glutathione metabolism in argininosuccinic aciduria. bioRxiv https://doi.org/10.1101/2022.10.19.512931

  • Häberle J, Chakrapani A, Ah Mew N, et al. 2018 Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories. Orphanet J. Rare Dis. 13 219

    Article  PubMed  PubMed Central  Google Scholar 

  • Haijes HA, Hasselt PM, Jans JJM, et al. 2019 Pathophysiology of propionic and methylmalonic acidemias. Part 2: Treatment strategies. J. Inherit. Metab. Dis. 42 745–761

    Article  PubMed  Google Scholar 

  • Hald Albertsen C, Kulkarni JA, Witzigmann D, et al. 2022 The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188 114416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hanssens LS, Duchateau J and Casimir GJ 2021 CFTR protein: Not just a chloride channel? Cells 10

  • Haque A, Dewerth A, Antony JS, et al. 2018 Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Sci. Rep. 8 16776

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  • Harris DA, Hayes KN, Zullo AR, et al. 2023 Comparative risks of potential adverse events following COVID-19 mRNA vaccination among older US adults. JAMA Netw. Open 6 e2326852–e2326852

    Article  PubMed  PubMed Central  Google Scholar 

  • Hart DP, Matino D, Astermark J, et al. 2022 International consensus recommendations on the management of people with haemophilia B. Ther. Adv. Hematol. 13 20406207221085200

    Article  PubMed  PubMed Central  Google Scholar 

  • Hasegawa T, Tzakis AG, Todo S, et al. 1995 Orthotopic liver transplantation for ornithine transcarbamylase deficiency with hyperammonemic encephalopathy. J. Pediatr. Surg. 30 863–865

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hassett KJ, Benenato KE, Jacquinet E, et al. 2019 Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15 1–11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hennermann JB, Roloff S, Gellermann J, et al. 2013 Chronic kidney disease in adolescent and adult patients with phenylketonuria. J. Inherit. Metab. Dis. 36 747–756

    Article  CAS  PubMed  Google Scholar 

  • Herrera-Barrera M, Ryals RC, Gautam M, et al. 2023 Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci. Adv. 9 eadd4623

    Article  PubMed  PubMed Central  Google Scholar 

  • Hou X, Zaks T, Langer R, et al. 2021 Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6 1078–1094

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang D, Yue F, Qiu J, et al. 2020 Polymeric nanoparticles functionalized with muscle-homing peptides for targeted delivery of phosphatase and tensin homolog inhibitor to skeletal muscle. Acta Biomater. 118 196–206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang X, Ma Y, Li Y, et al. 2021 Targeted drug delivery systems for kidney diseases. Front. Bioeng. Biotechnol. 9 683247

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang X, Kong N, Zhang X, et al. 2022 The landscape of mRNA nanomedicine. Nat. Med. 28 2273–2287

    Article  CAS  PubMed  Google Scholar 

  • Indian Organization for Rare Diseases 2022 US FDA approved Hemgenix to cost Rs 28.52 Crore! (https://www.rarediseases.in/us-fda-approved-hemgenix-to-cost-rs-28-52-crore/)

  • Inglut CT, Sorrin AJ, Kuruppu T, et al. 2020 Immunological and toxicological considerations for the design of liposomes. Nanomaterials 10 190

  • Jayaraman M, Ansell SM, Mui BL, et al. 2012 Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51 8529–8533

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang Z and Dalby PA 2023 Challenges in scaling up AAV-based gene therapy manufacturing. Trends Biotechnol. 41 1268–1281

    Article  CAS  PubMed  Google Scholar 

  • Jiang L, Berraondo P, Jericó D, et al. 2018 Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat. Med. 24 1899–1909

    Article  CAS  PubMed  Google Scholar 

  • Jiang L, Park J-S, Yin L, et al. 2020 Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat. Commun. 11 5339

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnson V 2021 Astellas pauses gene therapy trial for X-linked myotubular myopathy. (https://www.cgtlive.com/view/astellas-pauses-gene-therapy-trial-x-linked-myotubular-myopathy)

  • Ju Y, Lee WS, Pilkington EH, et al. 2022 Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16 11769–11780

    Article  CAS  PubMed  Google Scholar 

  • Karadagi A, Cavedon AG, Zemack H, et al. 2020 Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency. Sci. Rep. 10 7052

  • Karikó K, Buckstein M, Ni H, et al. 2005 Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 23 165–175

    Article  PubMed  Google Scholar 

  • Karikó K, Muramatsu H, Welsh FA, et al. 2008 Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16 1833–1840

    Article  PubMed  Google Scholar 

  • Karikó K, Muramatsu H, Ludwig J, et al. 2011 Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39 e142

    Article  PubMed  PubMed Central  Google Scholar 

  • Kedmi R, Ben-Arie N and Peer D 2010 The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31 6867–6875

    Article  CAS  PubMed  Google Scholar 

  • Khoja S, Liu X-B, Truong B, et al. 2022 Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency. Mol. Ther. Nucleic Acids. 28 859–874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim EM, Bae YM, Choi MH, et al. 2012 Cyst formation, increased anti-inflammatory cytokines and expression of chemokines support for Clonorchis sinensis infection in FVB mice. Parasitol. Int. 61 124–129

    Article  CAS  PubMed  Google Scholar 

  • Kim M, Jeong M, Hur S, et al. 2021 Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7 eabf4398

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim M, Jeong M, Lee G, et al. 2023 Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety. Bioeng. Transl. Med. https://doi.org/10.1002/btm2.10556

    Article  PubMed  PubMed Central  Google Scholar 

  • Kishimoto TK and Samulski RJ 2022 Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’? Expert Opin. Biol. Ther. 22 1067–1071

    Article  PubMed  Google Scholar 

  • Kishnani PS, Austin SL, Abdenur JE, et al. 2014 Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet. Med. 16 e1–e29

    Article  CAS  PubMed  Google Scholar 

  • Kitagawa H, Kaiki Y, Sugiyama A, et al. 2022 Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J. Infect. Chemother. 28 576–581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Klein NP, Lewis N, Goddard K, et al. 2021 Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326 1390–1399

    Article  CAS  PubMed  Google Scholar 

  • Knoebl P, Thaler J, Jilma P, et al. 2021 Emicizumab for the treatment of acquired hemophilia A. Blood 137 410–419

    Article  CAS  PubMed  Google Scholar 

  • Koynova R, Tenchov B, Wang L, et al. 2009 Hydrophobic moiety of cationic lipids strongly modulates their transfection activity. Mol. Pharm. 6 951–958

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ledermann JA, Canevari S and Thigpen T 2015 Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann. Oncol. 26 2034–2043

    Article  CAS  PubMed  Google Scholar 

  • Lee J-A, Cho A, Huang EN, et al. 2021 Gene therapy for cystic fibrosis: new tools for precision medicine. J. Transl. Med. 19 452

    Article  PubMed  PubMed Central  Google Scholar 

  • Lek A, Wong B, Keeler A, et al. 2023 Unexpected death of a duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-delivered CRISPR-transactivator. MedRxiv https://doi.org/10.1101/2023.05.16.23289881

  • Leppek K, Byeon GW, Kladwang W, et al. 2022 Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13 1536

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Levy HL and Ghavami M 1996 Maternal phenylketonuria: a metabolic teratogen. Teratology 53 176–184

    Article  CAS  PubMed  Google Scholar 

  • Li T, Yang Y, Qi H, et al. 2023 CRISPR/Cas9 therapeutics: progress and prospects. Signal. Transduct. Target. Ther. 8 36

    Article  PubMed  PubMed Central  Google Scholar 

  • Light DW and Lexchin J 2021 The costs of coronavirus vaccines and their pricing. J. R. Soc. Med. 114 502–504

    Article  PubMed  Google Scholar 

  • Liu-Chen S, Connolly B, Cheng L, et al. 2018 mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice. Sci. Rep. 8 7859

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  • Lopes C, Cristóvão J, Silvério V, et al. 2022 Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. Expert Opin. Drug. Deliv. 19 1381–1395

    Article  CAS  PubMed  Google Scholar 

  • Lou B, De Koker S, Lau CYJ, et al. 2019 mRNA polyplexes with post-conjugated GALA peptides efficiently target, transfect, and activate antigen presenting cells. Bioconjug. Chem. 30 461–475

    Article  ADS  CAS  PubMed  Google Scholar 

  • Lv H, Zhang S, Wang B, et al. 2006 Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of controlled release. J. Control Release 114 100–109

    Article  CAS  PubMed  Google Scholar 

  • Mahajan R 2019 Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever. Int. J. Appl. Basic. Med. Res. 9 127–128

    Article  PubMed  PubMed Central  Google Scholar 

  • Manoharan M, Kallanthottathil GR, Muthusamy, et al. 2014 Lipids and compositions for the delivery of therapeutics US Patent US8722082B2.

  • Manoli I, Sysol JR, Li L, et al. 2013 Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. Proc. Natl. Acad. Sci. USA 110 13552–13557

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • McCafferty EH and Scott LJ 2019 Migalastat: A review in Fabry disease. Drugs 79 543–554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meyer RA, Neshat SY, Green JJ, et al. 2022 Targeting strategies for mRNA delivery. Mater. Today Adv. 14 100240

    Article  CAS  Google Scholar 

  • Miao HZ, Sirachainan N, Palmer L, et al. 2004 Bioengineering of coagulation factor VIII for improved secretion. Blood 103 3412–3419

    Article  CAS  PubMed  Google Scholar 

  • Ministry of Health and Family Welfare 2022 Rare diseases cell (https://main.mohfw.gov.in/sites/default/files/Meta%20Data-%20Rare%20Diseases%20Cell%20%28Grants%20Section%29-2-3_1.pdf)

  • Moderna I 2020 United States Securities and Exchange Commission (https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/mrna-20201231.htm)

  • Moderna I 2022 Ornithine transcarbamylase deficiency (mRNA-3139) (https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2022/11/OTC-(11-03-22).pdf)

  • ModernaTX I 2023 Cystic fibrosis (CF) (VX-522) JP Morgan Healthcare Conference (https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2023/05/Cystic-Fibrosis-05-04-23.pdf)

  • mRNA pipeline of Moderna Inc. 2023 (https://www.modernatx.com/research/product-pipeline)

  • Mu LM, Bu YZ, Liu L, et al. 2017 Lipid vesicles containing transferrin receptor binding peptide TfR-T(12) and octa-arginine conjugate stearyl-R(8) efficiently treat brain glioma along with glioma stem cells. Sci. Rep. 7 3487

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  • Mullard A 2023 FDA approves gene therapy for DMD. Nat. Rev. Drug Discov. 22

  • Muranjan M and Karande S 2018 Enzyme replacement therapy in India: Lessons and insights. J. Postgrad. Med. 64 195–199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Naddaf M 2022 $3.5-Million hemophilia gene therapy is world’s most expensive drug (https://www.scientificamerican.com/article/3-5-million-hemophilia-gene-therapy-is-worlds-most-expensive-drug/)

  • National Policy For Treatment Of Rare Diseases 2017 Ministry of Health and Family Welfare. In: https://main.mohfw.gov.in/sites/default/files/Rare%20Diseases%20Policy%20FINAL.pdf.

  • National Policy For Treatment Of Rare Diseases 2021 Ministry of Health and Family Welfare. In: https://rarediseases.mohfw.gov.in/uploads/Content/1624967837_Final-NPRD-2021.pdf.

  • NCT02991144 2016 Ultragenyx Pharmaceutical Inc. Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency.

  • NCT03375047 2017 Translate Bio, Inc. Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis.

  • NCT03938792 2019 Pfizer, Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B.

  • NCT04159103 2019 ModernaTX, Inc. Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia.

  • NCT04899310 2021 ModernaTX, Inc. A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia.

  • NCT05092685 2021 University College, London Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in Children.

  • NCT05095727 2021 ModernaTX, Inc. A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a).

  • NCT05130437 2021a ModernaTX, Inc A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927.

  • NCT05130437 2021b ModernaTX, Inc. A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927.

  • NCT05668741 2022 Vertex Pharmaceuticals Incorporated, A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF).

  • NCT05712538 2023 Arcturus Therapeutics, Inc., safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects.

  • NCT05737485 2023 ReCode Therapeutics Study Evaluating the Safety and Tolerability of RCT1100 in Healthy Subjects.

  • Ndeupen S, Qin Z, Jacobsen S, et al. 2021 The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 24 103479

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Nelson J, Sorensen EW, Mintri S, et al. 2020 Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6 eaaz6893

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Nuzbrokh Y, Ragi SD and Tsang SH 2021 Gene therapy for inherited retinal diseases. Ann. Transl. Med. 9 1278

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ohashi T 2012 Enzyme replacement therapy for lysosomal storage diseases. Pediatr. Endocrinol. Rev. 10 26–34

    PubMed  Google Scholar 

  • Orlandini von Niessen AG, Poleganov MA, Rechner C, et al. 2019 Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening. Mol. Ther. 27 824–836

    Article  CAS  PubMed  Google Scholar 

  • Paramasivam P, Franke C, Stöter M, et al. 2022 Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. J. Cell Biol. 221

  • Pardi N, Hogan MJ, Porter FW, et al. 2018 mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17 261–279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Paulk N 2020 Gene therapy: It’s time to talk about high-dose AAV (https://www.genengnews.com/insights/gene-therapy-its-time-to-talk-about-high-dose-aav/)

  • Perez-Garcia CG, Diaz-Trelles R, Vega JB, et al. 2022 Development of an mRNA replacement therapy for phenylketonuria. Mol. Ther. Nucleic. Acids. 28 87–98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pfizer 2022 Pfizer and Beam enter exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research)

  • Pharmacoeconomic Review Report 2018 Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Appendix 1, Cost Comparison (https://www.ncbi.nlm.nih.gov/books/NBK533452/)

  • Philippidis A 2021 Fourth boy dies in trial of Astellas gene therapy candidate (https://www.genengnews.com/news/fourth-boy-dies-in-trial-of-astellas-gene-therapy-candidate/)

  • Philippidis A 2022a After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Hum. Gene Ther. 33 111–115

    Article  CAS  Google Scholar 

  • Philippidis A 2022b Novartis confirms deaths of two patients treated with gene therapy zolgensma. Hum. Gene Ther. 33 842–844

    Article  CAS  PubMed  Google Scholar 

  • Pradhan-Sundd T, Gudapati S, Kaminski TW, et al. 2021 Exploring the complex role of coagulation factor VIII in chronic liver disease. Cell Mol. Gastroenterol. Hepatol. 12 1061–1072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prieve MG, Harvie P, Monahan SD, et al. 2018 Targeted mRNA therapy for ornithine transcarbamylase deficiency. Mol. Ther. 26 801–813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Qin S, Tang X, Chen Y, et al. 2022 mRNA-based therapeutics: powerful and versatile tools to combat diseases. Sig. Trans. Target. Ther. 7 166

    Article  CAS  Google Scholar 

  • Qiu M, Tang Y, Chen J, et al. 2022 Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA 119

  • Rajas F, Gautier-Stein A and Mithieux G 2019 Glucose-6 phosphate, a central hub for liver carbohydrate metabolism. Metabolites 9 282

  • Rajasimha HK, Shirol PB, Ramamoorthy P, et al. 2014 Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases’ community. Genet. Res. 96 e009

    Article  Google Scholar 

  • Ramaswamy S, Tonnu N, Tachikawa K, et al. 2017 Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl. Acad. Sci. USA 114 E1941–E1950

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rexaline S 2019 Translate Bio halts mRNA therapy trial (https://finance.yahoo.com/news/daily-biotech-pulse-translate-bio-113612732.html)

  • Rizvi ZKaZ 2021 How to make enough vaccine for the world in one year (https://www.citizen.org/article/how-to-make-enough-vaccine-for-the-world-in-one-year/#_ftn31)

  • Robinson E, MacDonald KD, Slaughter K, et al. 2018 Lipid nanoparticle-delivered chemically modified mRNA Restores chloride secretion in cystic fibrosis. Mol. Ther. 26 2034–2046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rohner E, Yang R, Foo KS, et al. 2022 Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40 1586–1600

    Article  CAS  PubMed  Google Scholar 

  • Rosa SS, Prazeres DMF, Azevedo AM, et al. 2021 mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 39 2190–2200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roseman DS, Khan T, Rajas F, et al. 2018 G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a. Mol. Ther. 26 814–821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rowe SM, Zuckerman JB, Dorgan D, et al. 2023 Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J. Cystic Fibrosis 22 656–664

    Article  CAS  Google Scholar 

  • Sabnis S, Kumarasinghe ES, Salerno T, et al. 2018 A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26 1509–1519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saheki T SY 2005 Citrin deficiency; in GeneReviews (University of Washington) (https://www.ncbi.nlm.nih.gov/books/NBK1181/)

  • Sahin U, Karikó K and Türeci Ö 2014 mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug. Discov. 13 759–780

    Article  CAS  PubMed  Google Scholar 

  • Sakamoto O, Ohura T, Matsubara Y, et al. 2007 Mutation and haplotype analyses of the MUT gene in Japanese patients with methylmalonic acidemia. J. Hum. Genet. 52 48–55

    Article  CAS  PubMed  Google Scholar 

  • Sato Y, Kinami Y, Hashiba K, et al. 2020 Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway. J. Control Release 322 217–226

    Article  CAS  PubMed  Google Scholar 

  • Schlich M, Palomba R, Costabile G, et al. 2021 Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioeng. Transl. Med. 6 e10213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schoenmaker L, Witzigmann D, Kulkarni JA, et al. 2021 mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int. J. Pharm. 601 120586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sedic M, Senn JJ, Lynn A, et al. 2017 Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet. Pathol. 55 341–354

    Article  PubMed  Google Scholar 

  • Sellers DL, Tan J-KY, Pineda JMB, et al. 2019 Targeting ligands deliver model drug cargo into the central nervous system along autonomic neurons. ACS Nano 13 10961–10971

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Semple SC, Akinc A, Chen J, et al. 2010 Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28 172–176

    Article  CAS  PubMed  Google Scholar 

  • Shabu A and Nishtala PS 2023 Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine. Expert Rev. Vaccines 22 801–812

    Article  CAS  PubMed  Google Scholar 

  • Shen W, Liu S and Ou L 2022 rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front. Immunol. 13 1001263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spiritos Z, Salvador S, Mosquera D, et al. 2019 Acute intermittent porphyria: current perspectives and case presentation. Ther. Clin. Risk Manag. 15 1443–1451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Starzyk K, Richards S, Yee J, et al. 2007 The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol. Genet. Metab. 90 157–163

    Article  CAS  PubMed  Google Scholar 

  • Strauss KA, Ahlfors CE, Soltys K, et al. 2020 Crigler-Najjar syndrome type 1: Pathophysiology, natural history, and therapeutic frontier. Hepatology 71 1923–1939

    Article  CAS  PubMed  Google Scholar 

  • Szebeni J, Muggia F, Gabizon A, et al. 2011 Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention. Adv. Drug Del. Rev. 63 1020–1030

    Article  CAS  Google Scholar 

  • Tahtinen S, Tong A-J, Himmels P, et al. 2022 IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23 532–542

    Article  CAS  PubMed  Google Scholar 

  • Takano S, Aramaki Y and Tsuchiya S 2003 Physicochemical properties of liposomes affecting apoptosis induced by cationic liposomes in macrophages. Pharm. Res. 20 962–968

    Article  CAS  PubMed  Google Scholar 

  • Tanne JH 2022 FDA approves $3.5m gene therapy for adults with haemophilia B. Br. Med. J. 379 o2858

    Article  Google Scholar 

  • Tanner SM and Lorenz RG 2022 FVB/N mouse strain regulatory T cells differ in phenotype and function from the C57BL/6 and BALB/C strains. FASEB Bioadv. 4 648–661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tateshita N, Miura N, Tanaka H, et al. 2019 Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine. J. Control Release 310 36–46

    Article  CAS  PubMed  Google Scholar 

  • Taylor NP 2020 Astellas' Audentes reports 3rd death in gene therapy trial (https://www.fiercebiotech.com/biotech/astellas-audentes-reports-third-death-gene-therapy-trial)

  • Taylor NP 2022 Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data (https://www.fiercebiotech.com/biotech/astellas-takes-170m-hit-dmd-gene-therapy-plan-unravels-wake-preclinical-data)

  • Temaj G, Nuhii N and Sayer JA 2022 The impact of consanguinity on human health and disease with an emphasis on rare diseases. J. Rare Disease 1 2

    Article  Google Scholar 

  • The Lancet Diabetes Endocrinology 2019 Spotlight on rare diseases. Lancet Diabetes Endocrinol. 7 75

  • Thi TTH, Suys EJA, Lee JS, et al. 2021 Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccine 9 359

    Article  CAS  Google Scholar 

  • Translate Bio, Inc. 2018 United States Securities and Exchange Commission (https://www.sec.gov/Archives/edgar/data/1693415/000119312518181734/d523294ds1.htm)

  • Truong B, Allegri G, Liu XB, et al. 2019 Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc. Natl. Acad. Sci. USA 116 21150–21159

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Ugarte M, Pérez-Cerdá C, Rodríguez-Pombo P, et al. 1999 Overview of mutations in the PCCA and PCCB genes causing propionic acidemia. Hum. Mutat. 14 275–282

    Article  CAS  PubMed  Google Scholar 

  • Urits I, Swanson D, Swett MC, et al. 2020 A Review of Patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neur. Ther. 9 301–315

    Article  Google Scholar 

  • van Spronsen FJ, Hoeksma M and Reijngoud D-J 2009 Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause? J. Inherit. Metab. Dis. 32 46

    Article  PubMed  Google Scholar 

  • van Spronsen FJ, Blau N, Harding C, et al. 2021 Phenylketonuria. Nat. Rev. Dis. Primers 7 36

    Article  PubMed  PubMed Central  Google Scholar 

  • Vara R, Turner C, Mundy H, et al. 2011 Liver transplantation for propionic acidemia in children. Liver Transpl. 17 661–667

    Article  PubMed  Google Scholar 

  • Verma IC and Puri RD 2015 Global burden of genetic disease and the role of genetic screening. Semin. Fetal Neonatal Med. 20 354–363

    Article  CAS  PubMed  Google Scholar 

  • Vogel AB, Kanevsky I, Che Y, et al. 2021 BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592 283–289

    Article  ADS  CAS  PubMed  Google Scholar 

  • Wang L, Bell P, Morizono H, et al. 2017 AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Mol. Genet. Metab. 120 299–305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wanner C, Kimonis V, Politei J, et al. 2022 Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. Mol. Genet. Metab. Rep. 31 100862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wesselhoeft RA, Kowalski PS and Anderson DG 2018 Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9 2629

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  • Wesselhoeft RA, Kowalski PS, Parker-Hale FC, et al. 2019 RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell 74 508-520.e504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wilson JM 2009 Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol. Genet. Metab. 96 151–157

    Article  CAS  PubMed  Google Scholar 

  • Witmer C and Young G 2013 Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther. Adv. Hematol. 4 59–72

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wongkittichote P, Ah Mew N and Chapman KA 2017 Propionyl-CoA carboxylase - A review. Mol. Genet. Metab. 122 145–152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xiang Z, Kurupati RK, Li Y, et al. 2020 The effect of CpG sequences on capsid-specific CD8+ T cell responses to AAV vector gene transfer. Mol. Ther. 28 771–783

    Article  CAS  PubMed  Google Scholar 

  • Yamazaki K, Kubara K, Ishii S, et al. 2023 Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice. Mol. Ther. Nucl. Acids. 33 210–226

    Article  CAS  Google Scholar 

  • Yu H, Brewer E, Shields M, et al. 2022 Restoring ornithine transcarbamylase (OTC) activity in an OTC-deficient mouse model using LUNAR-OTC mRNA. Clin. Transl. Discov. 2 e33

    Article  Google Scholar 

  • Zariwala MA, Leigh MW, Ceppa F, et al. 2006 Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation. Am. J. Respir. Crit. Care. Med. 174 858–866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zelphati O and Szoka FC Jr 1996 Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 93 11493–11498

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang H, Zhang L, Lin A, et al. 2023 Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621 396–403

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao Z, Ukidve A, Kim J, et al. 2020 Targeting strategies for tissue-specific drug delivery. Cell 181 151–167

    Article  CAS  PubMed  Google Scholar 

  • Zhou Q and Qiu H 2019 The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins. J. Pharm. Sci. 108 1366–1377

    Article  CAS  PubMed  Google Scholar 

  • Zhu X, Yin L, Theisen M, et al. 2019 Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am. J. Hum. Genet. 104 625–637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr. Alok Bhattacharya for his insightful comments on the manuscript.

Funding

The study is supported by the funding from Tata Trusts.

Author information

Authors and Affiliations

  1. Tata Institute for Genetics and Society, GKVK-NCBS campus, Bengaluru, India

    V Rajesh Iyer, P Praveen, Bhagyashree D Kaduskar, Shivranjani C Moharir & Rakesh K Mishra

Authors
  1. V Rajesh Iyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Praveen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhagyashree D Kaduskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shivranjani C Moharir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rakesh K Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V Rajesh Iyer.

Additional information

Corresponding editor: Sudha Bhattacharya

This article is part of the Topical Collection: The Rare Genetic Disease Research Landscape in India.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 46 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iyer, V.R., Praveen, P., Kaduskar, B.D. et al. mRNA biotherapeutics landscape for rare genetic disorders. J Biosci 49, 33 (2024). https://doi.org/10.1007/s12038-023-00415-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12038-023-00415-6

Keywords

Search

Navigation